Advertisement

Topics

Latest "Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018" News Stories - Page: 3

17:32 EDT 18th March 2019 | BioPortfolio

Here are the most relevant search results for "Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018" found in our extensive news archives from over 250 global news sources.

More Information about Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018 on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018 for you to read. Along with our medical data and news we also list Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018 Clinical Trials, which are updated daily. BioPortfolio also has a large database of Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018 Companies for you to search.

Showing "Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018" News Articles 51–75 of 37,000+

Monday 18th March 2019

STAT Plus: A Regeneron drug dominates eczema treatment. With new data, a small biotech believes it can compete

Regeneron's Dupixent is a commercial blockbuster. Now the small biotech Dermira could challenge that dominance in eczema treatment.


Imara raises $63m for sickle cell drug trials

US biotech Imara has raised $63 million for clinical development of its sickle cell disease drug, which is in mid-stage development. Imara attracted investors including Arix Bioscience, which has invested $15 million for a 10% stake, and will also...

Fresenius Medical Care AG & Co. KGaA: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements

Fresenius Medical Care AG & Co. KGaA / Preliminary announcement on the disclosure of financial statements 18.03.2019 / 10:28 Preliminary announcement of the publication of quarterly reports and quarterly/interim statements transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. -------------------------------------------------------...


Fresenius Medical Care AG & Co. KGaA: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

Fresenius Medical Care AG & Co. KGaA / Preliminary announcement on the disclosure of financial statements 18.03.2019 / 10:25 Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. ------------...

MCG Health’s Dr. Sabitha Rajan to Speak at 2019 Society of Hospital Medicine Conference

Associate Managing Editor of the nationally recognized MCG care guidelines will co-present on medically complex patients SEATTLE (PRWEB) March 18, 2019 MCG Health, part of the Hearst Health network, and a leading provider of informed care strategies, announces Associate Managing Editor, Sabitha Rajan, MD, MSc, will speak at the Society of Hospital Medicine (SHM) annual conference on Mar. 25, 2019...

Prevencio Announces Two Validation Studies Confirming High Accuracy of Novel HART AI-driven Tests

Compelling Data for HART CVE™ Test for Cardiovascular Events and HART CAD™ Test for Coronary Artery Disease Prevencio, Inc. today announces data confirming the high accuracy of its AI-driven, multiple-protein HART CVE Test for predicting Cardiovascular Events (CVE) and HART CAD Test for diagnosing Coro

Cellesce Announces License Agreement with Hubrecht Organoid Technology (HUB) for the Expansion of Breast Cancer Organoids at Scale

CARDIFF, UK, March 18, 2019 / B3C newswire / -- Cellesce and Hubrecht Organoid Technology (HUB) have today announced a licence agreement for the expansion of organoids using Cellesce’s own bioprocessing technology and HUB Organoid Technology for the scale up of breast organoids. Cellesce and HUB have an ongoing agreement for the expansion of organoids using HUB Technology. In a new project, fun...

Global Regenerative Medicine Market to Witness a CAGR of 20.5% during 2018-2024

NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) Read more...

Dermira shares double on positive eczema data

The dermatology-focused biotech is now mulling a late-stage trial that would test two higher-dose regimens of its drug, lebrikizumab.

LIDDS to evaluate a possible listing of the company's shares on Nasdaq Stockholm's Main Market during 2020

STOCKHOLM - LIDDS (Nasdaq First North: LIDDS) announced today that the company will evaluate a possible listing of its shares on Nasdaq Stockholm's Main Market during 2020 and will engage advisors to explore this potential relisting. LIDDS is in a strong growth and expansion phase with several key projects in clinical and pre-clinical phases, including the Phase IIb Liproca® Depot s...

Pipeline Watch: Phase III Starts In PTSD, Ulcerative Colitis And Prader-Willi Syndrome

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...   

Actinogen Medical - Differentiated treatment for Alzheimer's disease

Edison Investment Research - Pharmaceuticals & healthcare - Actinogen Medical: Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem to treat cognitive impairment ...

AEVIS VICTORIA SA: Infracore SA publishes its first Annual Report based on Swiss GAAP FER with properties valued at their market value

AEVIS VICTORIA SA / Key word(s): Miscellaneous 18-March-2019 / 07:20 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Press release Fribourg, 18 March 2019 AEVIS VICTORIA SA: Infracore SA publishes its first Annual Report based on Swiss GAAP FER with properties valued at their market value Infraco...

Alcon Announces Acquisition of PowerVision, Inc.

Novartis International AG / Alcon Announces Acquisition of PowerVision, Inc. . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement.  Acquisition demonstrates Alcon's commitment to driving growth and innovation in advanced technology intraocular lenses (AT-IOLS) to meet the needs of cataract surgery patients who...

MDxHealth (R): MDxHealth Announces Positive Data from Pan-European Clinical Validation Study of SelectMDx

 NEWS RELEASE                                                                                                               SelectMDx demonstrates accurate identification of both low-risk and aggressive prostate cancer across all patient groups IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CET, March 18, 2019 - MDxHealth SA ...

Applied BioSciences Announces Record Revenue

LOS ANGELES, March 18, 2019 (GLOBE NEWSWIRE) Read more...

Poxel Announces Participation at the Oppenheimer 29th Annual Healthcare Conference

POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), announced today that it will be featured as a presenting company at the Oppenheimer 29th Annual Healthcare Conference.

Kyowa Kirin Asia Pacific Announces Establishment of Subsidiary in Australia

Kyowa Kirin Asia Pacific Pte. Ltd. (President: Chikakuni Kotani, Kyowa Kirin Asia Pacific), a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (President & COO: Masashi Miyamoto, Kyowa Hakko Kirin), announces it has established an Australian subsidiary, named Kyowa Kirin Australia Pty Ltd (Kyowa Kirin Australia). With the establishment of Kyowa Kirin ...

American Premium Water Corp. (OTC:HIPH) Announces Agreement with Hanlons Brewery in United ...

PLAYA VISTA, Calif., March 18, 2019 (GLOBE NEWSWIRE) Read more...

Novartis International AG: Alcon Announces Acquisition of PowerVision, Inc.

Novartis International AG / Alcon Announces Acquisition of PowerVision, Inc. . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. ...

TLC Announces First Patient Dosed in Phase II Trial of TLC590 for Postsurgical Pain Management ...

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 18, 2019 (GLOBE NEWSWIRE) Read more...

Sunday 17th March 2019

VWR Sheldon Model 2005 Low Temperature Incubator Laboratory

C $1,100.00End Date: Saturday Apr-6-2019 9:25:50 EDTBuy It Now for only: C $1,100.00Buy It Now | Add to watch list Biotech365 : VWR Sheldon Model 2005 Low Temperature Incubator Laboratory BioMarketplace You want to propose your products or a Biotech … Continue reading →

VWR Stirrer Hotplate VMS-C7 S1-DG

C $26.67 (0 Bids)End Date: Wednesday Mar-20-2019 14:47:14 EDTBid now | Add to watch list Biotech365 : VWR Stirrer Hotplate VMS-C7 S1-DG BioMarketplace You want to propose your products or a Biotech Company, a Biotech Tool or a Bioinformatic software … Continue reading →

Veco Thermistor 32A503 for RF power measurement like HP Agilent 432

50,00 EUR (0 Pujas)Fecha de finalización: domingo mar-24-2019 15:07:41 CETPujar ahora | Añadir a lista de seguimiento Biotech365 : Veco Thermistor 32A503 for RF power measurement like HP Agilent 432 BioMarketplace You want to propose your products or a Biotech … Continue reading →

CancerIQ Platform More than Doubles Number of Patients Identified as Eligible for MRI Surveillance to Detect Cancer Earlier

Riverside Healthcare presented data at the NCBC Conference, where CancerIQ also announced new partnership agreements with Cordata, MRS, and PenRad CHICAGO (PRWEB) March 17, 2019 Riverside Healthcare and Cancer IQ, Inc. presented the results of a 24-month study of a high-risk program to screen and identify women at elevated risk for hereditary cancer in the mammography setting at the National Cons...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks